Report cover image

NA Cancer Immunotherapy Market - Industry Trends and Forecast to 2035

Publisher Data Bridge Market Research
Published Dec 01, 2023
Length 251 Pages
SKU # DAABD18458900

Description

NA Cancer Immunotherapy Market - Industry Trends and Forecast to 2035


The North America cancer immunotherapy market is expected to reach USD 147,824.58 million by 2031 from USD 52,159.29 million in 2023, growing at a CAGR of 14.9% during the forecast period of 2024 to 2031.
Market Segmentation
North America Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031

Overview of North America Cancer Immunotherapy Market Dynamics

Driver
• Rising prevalence of cancer incidences

Restrain

• Increasing occurrence of immune-related adverse events

Opportunity

• Growing trend towards combination therapies

Market Players

Some of the major market players operating in the North America cancer immunotherapy market are:

• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Janssen Pharmaceutical
• AstraZeneca
• Gilead Sciences, Inc.
• Eli Lilly and Company
• Amgen Inc.
• Novartis AG
• GSK
• Pfizer Inc.
• Incyte

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

Table of Contents

251 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The North America Cancer Immunotherapy Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Product Type Segment Lifeline Curve
2.8 Market End User Coverage Grid
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestal Analysis
4.2 Porters 5 Forces
5 North America Cancer Immunotherapy Market: Regulations
6 Market Overview
6.1 Drivers
6.1.1 Rising Prevalence Of Cancer Incidences
6.1.2 Rising Technological Advancements
6.1.3 Increased Understanding Of Tumor Microenvironment
6.1.4 Rise In Patient Awareness And Demand For Targeted Treatment
6.2 Restraints
6.2.1 Increasing Occurrence Of Immune-related Adverse Events
6.2.2 Developing Resistance To Cancer Treatment
6.3 Opportunities
6.3.1 Growing Trend Towards Combination Therapies
6.3.2 Rising Integration Of Artificial Intelligence And Digital Health Tools
6.3.3 Development Of Next-generation Immunotherapies
6.4 Challenges
6.4.1 Lack Of Standardization In Biomarker Testing
6.4.2 Complexity Of Developing And Implementing Personalized Medicine
7 North America Cancer Immunotherapy Market, By Product Type
7.1 Overview
7.2 Checkpoint Inhibitors
7.2.1 Programmed Death 1 (Pd-1) & Programmed Death Ligand 1 (Pd-l1)
7.2.2 Cytotoxic T-lymphocyte-associated Protein-4 (Ctla-4)
7.3 Monoclonal Antibodies
7.3.1 Naked Monoclonal Antibodies
7.3.2 Conjugated Monoclonal Antibodies
7.3.3 Bispecific Monoclonal Antibodies
7.4 Vaccines
7.4.1 Prophylactic Vaccines
7.4.2 Therapeutic Vaccines
7.5 Cell Therapies
7.5.1 Chimeric Antigen Receptor (Car) T Cell Therapy
7.5.2 T Cell Therapy
7.6 Immunomodulators
7.6.1 Interferons
7.6.2 Interleukins
7.6.3 Granulocyte-macrophage Colony-stimulating Factor
7.7 Oncolytic Virus
8 North America Cancer Immunotherapy Market, By End User
8.1 Overview
8.2 Hospitals
8.3 Oncology Clinics
8.4 Homecare
8.5 Others
9 North America Cancer Immunotherapy Market, By Distribution Channel
9.1 Overview
9.2 Direct Tenders
9.3 Retail Sales
9.4 Pharmacies
9.4.1 Hospital
9.4.2 Retail
9.4.3 Online
10 North America Cancer Immunotherapy Market, By Form
10.1 Overview
10.2 Intravenous (Iv)
10.3 Intramuscular
10.4 Oral
11 North America Cancer Immunotherapy Market, By Application
11.1 Overview
11.2 Lung Cancer
11.2.1 Checkpoint Inhibitors
11.2.2 Monoclonal Antibodies
11.2.3 Cell Therapies
11.2.4 Immunomodulators
11.3 Breast Cancer
11.3.1 Checkpoint Inhibitors
11.3.2 Monoclonal Antibodies
11.3.3 Cell Therapies
11.3.4 Immunomodulators
11.4 Melanoma
11.4.1 Checkpoint Inhibitors
11.4.2 Monoclonal Antibodies
11.4.3 Cell Therapies
11.4.4 Immunomodulators
11.4.5 Oncolytic Virus
11.5 Multiple Myeloma
11.5.1 Checkpoint Inhibitors
11.5.2 Monoclonal Antibodies
11.5.3 Cell Therapies
11.5.4 Immunomodulators
11.6 Prostate Cancer
11.6.1 Checkpoint Inhibitors
11.6.2 Monoclonal Antibodies
11.6.3 Cell Therapies
11.6.4 Immunomodulators
11.6.5 Vaccines
11.7 Ovarian Cancer
11.7.1 Checkpoint Inhibitors
11.7.2 Monoclonal Antibodies
11.7.3 Cell Therapies
11.7.4 Immunomodulators
11.8 Cervical Cancer
11.8.1 Checkpoint Inhibitors
11.8.2 Monoclonal Antibodies
11.8.3 Vaccines
11.8.4 Cell Therapies
11.8.5 Immunomodulators
11.9 Stomach Cancer
11.9.1 Checkpoint Inhibitors
11.9.2 Monoclonal Antibodies
11.9.3 Cell Therapies
11.9.4 Immunomodulators
11.10 Colorectal Cancer
11.10.1 Checkpoint Inhibitors
11.10.2 Monoclonal Antibodies
11.10.3 Cell Therapies
11.10.4 Immunomodulators
11.11 Head And Neck Cancer
11.11.1 Checkpoint Inhibitors
11.11.2 Monoclonal Antibodies
11.11.3 Cell Therapies
11.11.4 Immunomodulators
11.12 Others
11.12.1 Checkpoint Inhibitors
11.12.2 Monoclonal Antibodies
11.12.3 Vaccines
11.12.4 Cell Therapies
11.12.5 Immunomodulators
12 North America Cancer Immunotherapy Market, By Region
12.1 North America
12.1.1 U.S.
12.1.2 Canada
12.1.3 Mexico
13 North America Cancer Immunotherapy Market, Company Landscape
13.1 Company Share Analysis: North America
14 Swot Analysis
15 Company Profiles
15.1 Merck & Co., Inc.
15.1.1 Company Snapshot
15.1.2 Revenue Analysis
15.1.3 Company Share Analysis
15.1.4 Product Portfolio
15.1.5 Recent Developments
15.2 F. Hoffmann-la Roche Ltd
15.2.1 Company Snapshot
15.2.2 Revenue Analysis
15.2.3 Company Share Analysis
15.2.4 Product Portfolio
15.2.5 Recent Developments
15.3 Bristol-myers Squibb Company
15.3.1 Company Snapshot
15.3.2 Revenue Analysis
15.3.3 Company Share Analysis
15.3.4 Product Portfolio
15.3.5 Recent Developments
15.4 Janssen North America Services, Llc
15.4.1 Company Snapshot
15.4.2 Revenue Analysis
15.4.3 Company Share Analysis
15.4.4 Product Portfolio
15.4.5 Recent Developments
15.5 Astrazeneca
15.5.1 Company Snapshot
15.5.2 Revenue Analysis
15.5.3 Company Share Analysis
15.5.4 Product Portfolio
15.5.5 Recent Developments
15.6 Abbvie Inc.
15.6.1 Company Snapshot
15.6.2 Pipeline Portfolio
15.6.3 Recent Developments
15.7 Amgen Inc.
15.7.1 Company Snapshot
15.7.2 Revenue Analysis
15.7.3 Pipeline Portfolio
15.7.4 Product Portfolio
15.7.5 Recent Developments
15.8 Atara Biotherapeutics, Inc.
15.8.1 Company Snapshot
15.8.2 Pipeline Portfolio
15.8.3 Recent Developments
15.9 Bayer Ag
15.9.1 Company Snapshot
15.9.2 Pipeline Portfolio
15.9.3 Recent Developments
15.10 Celldex Therapeutics.
15.10.1 Company Snapshot
15.10.2 Pipeline Portfolio
15.10.3 Recent Developments
15.11 Cellectis
15.11.1 Company Snapshot
15.11.2 Pipeline Portfolio
15.11.3 Recent Developments
15.12 Gilead Sciences, Inc.
15.12.1 Company Snapshot
15.12.2 Revenue Analysis
15.12.3 Product Portfolio
15.12.4 Recent Developments
15.13 Gsk Plc.
15.13.1 Company Snapshot
15.13.2 Revenue Analysis
15.13.3 Product Portfolio
15.13.4 Recent Developments
15.14 Incyte.
15.14.1 Company Snapshot
15.14.2 Revenue Analysis
15.14.3 Product Portfolio
15.14.4 Recent Developments
15.15 Lilly.
15.15.1 Company Snapshot
15.15.2 Revenue Analysis
15.15.3 Product Portfolio
15.15.4 Recent Developments
15.16 Novartis Ag
15.16.1 Company Snapshot
15.16.2 Revenue Analysis
15.16.3 Pipeline Portfolio
15.16.4 Product Portfolio
15.16.5 Recent Developments
15.17 Pfizer Inc.
15.17.1 Company Snapshot
15.17.2 Revenue Analysis
15.17.3 Product Portfolio
15.17.4 Recent Developments
16 Questionnaire
17 Related Reports
List Of Tables
Table 1 North America Cancer Immunotherapy Market, By Product Type, 2022- 2031 (Usd Million)
Table 2 North America Checkpoint Inhibitors Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 3 North America Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 4 North America Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022- 2031 (Units)
Table 5 North America Monoclonal Antibodies In Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 6 North America Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 7 North America Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022- 2031 (Units)
Table 8 North America Vaccines In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 9 North America Vaccines In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 10 North America Vaccines In Cancer Immunotherapy Market, By Type, 2022- 2031 (Units)
Table 11 North America Cell Therapies In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 12 North America Cell Therapies In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 13 North America Cell Therapies In Cancer Immunotherapy Market, By Type, 2022- 2031 (Units)
Table 14 North America Immunomodulators In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 15 North America Immunomodulators In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 16 North America Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 17 North America Oncolytic Virus In Cancer Immunotherapymarket, By Region, 2022-2031 (Usd Million)
Table 18 North America Cancer Immunotherapy Market, By End User, 2022- 2031 (Usd Million)
Table 19 North America Hospitals In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 20 North America Oncology Clinics In Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 21 North America Homecare In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 22 North America Others In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 23 North America Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 24 North America Direct Tenders In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 25 North America Retail Sales In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 26 North America Pharmacies In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 27 North America Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 28 North America Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 29 North America Intravenous In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 30 North America Intramuscular In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 31 North America Oral In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 32 North America Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 33 North America Lung Canceri N Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 34 North America Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 35 North America Breast Canceri N Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 36 North America Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 37 North America Melanoma In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 38 North America Melanoma Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 39 North America Multiple Myeloma In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 40 North America Multiple Myeloma Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 41 North America Prostate Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 42 North America Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 43 North America Ovarianc Ancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 44 North America Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 45 North America Cervical Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 46 North America Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 47 North America Stomach Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 48 North America Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 49 North America Colorectal Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 50 North America Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 51 North America Head And Neck Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 52 North America Head & Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 53 North America Others In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 54 North America Others Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 55 North America Cancer Immunotherapy Market, By Country, 2022-2031 (Usd Million)
Table 56 North America Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 57 North America Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 58 North America Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 59 North America Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 60 North America Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 61 North America Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 62 North America Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 63 North America Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 64 North America Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 65 North America Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 66 North America Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 67 North America Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 68 North America Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 69 North America Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 70 North America Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 71 North America Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 72 North America Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 73 North America Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 74 North America Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 75 North America Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 76 North America Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 77 North America Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 78 North America Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 79 North America Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 80 North America Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 81 North America Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 82 North America Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 83 U.S. Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 84 U.S. Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 85 U.S. Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 86 U.S. Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 87 U.S. Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 88 U.S. Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 89 U.S. Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 90 U.S. Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 91 U.S. Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 92 U.S. Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 93 U.S. Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 94 U.S. Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 95 U.S. Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 96 U.S. Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 97 U.S. Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 98 U.S. Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 99 U.S. Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 100 U.S. Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 101 U.S. Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 102 U.S. Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 103 U.S. Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 104 U.S. Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 105 U.S. Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 106 U.S. Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 107 U.S. Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 108 U.S. Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 109 U.S. Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 110 U.S. Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 111 U.S. Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 112 U.S. Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 113 U.S. Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 114 U.S. Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 115 Canada Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 116 Canada Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 117 Canada Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 118 Canada Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 119 Canada Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 120 Canada Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 121 Canada Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 122 Canada Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 123 Canada Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 124 Canada Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 125 Canada Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 126 Canada Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 127 Canada Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 128 Canada Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 129 Canada Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 130 Canada Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 131 Canada Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 132 Canada Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 133 Canada Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 134 Canada Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 135 Canada Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 136 Canada Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 137 Canada Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 138 Canada Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 139 Canada Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 140 Canada Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 141 Canada Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 142 Canada Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 143 Canada Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 144 Canada Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 145 Canada Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 146 Canada Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 147 Mexico Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 148 Mexico Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 149 Mexico Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
List Of Figures
Figure 1 North America Cancer Immunotherapy Market: Segmentation
Figure 2 North America Cancer Immunotherapy Market: Data Triangulation
Figure 3 North America Cancer Immunotherapy Market: Droc Analysis
Figure 4 North America Cancer Immunotherapy Market: North America Vs Regional Market Analysis
Figure 5 North America Cancer Immunotherapy Market: Company Research Analysis
Figure 6 North America Cancer Immunotherapy Market: Interview Demographics
Figure 7 North America Cancer Immunotherapy Market: Market End User Coverage Grid
Figure 8 North America Cancer Immunotherapy Market: Dbmr Market Position Grid
Figure 9 North America Cancer Immunotherapy Market: Vendor Share Analysis
Figure 10 North America Cancer Immunotherapy Market: Segmentation
Figure 11 Rising Prevalence Of Cancer And Rising Technological Advancements Are Expected To Drive The Growth Of The North America Cancer Immunotherapy Market From 2024 To 2034
Figure 12 Checkpoint Inhibitors Segment Is Expected To Account For The Largest Share Of The North America Cancer Chemotherapy Consumables Market In 2024 To 2031
Figure 13 Drivers, Restraints, Opportunities, And Challenges Of North America Cancer Immunotherapy Market
Figure 14 North America Cancer Immunotherapymarket : By Product Type, 2023
Figure 15 North America Cancer Immunotherapymarket : By Product Type, 2024-2031 (Usd Million)
Figure 16 North America Cancer Immunotherapymarket : By Product Type, Cagr (2024-2031)
Figure 17 North America Cancer Immunotherapymarket : By Product Type, Lifeline Curve
Figure 18 North America Cancer Immunotherapymarket : By End User, 2023
Figure 19 North America Cancer Immunotherapymarket : By End User, 2024-2031 (Usd Million)
Figure 20 North America Cancer Immunotherapymarket : By End User, Cagr (2024-2031)
Figure 21 North America Cancer Immunotherapymarket : By End User, Lifeline Curve
Figure 22 North America Cancer Immunotherapy Market: By Distribution Channel, 2023
Figure 23 North America Cancer Immunotherapy Market: By Distribution Channel, 2024-2031 (Usd Million)
Figure 24 North America Cancer Immunotherapy Market: By Distribution Channel, Cagr (2024-2031)
Figure 25 North America Cancer Immunotherapy Market: By Distribution Channel, Lifeline Curve
Figure 26 North America Cancer Immunotherapy Market: By Form, 2023
Figure 27 North America Cancer Immunotherapy Market: By Form, 2024-2031 (Usd Million)
Figure 28 North America Cancer Immunotherapy Market: By Form, Cagr (2024-2031)
Figure 29 North America Cancer Immunotherapy Market: By Form, Lifeline Curve
Figure 30 North America Cancer Immunotherapy Market: By Application, 2023
Figure 31 North America Cancer Immunotherapy Market: By Application, 2024-2031 (Usd Million)
Figure 32 North America Cancer Immunotherapy Market: By Application, Cagr (2024-2031)
Figure 33 North America Cancer Immunotherapy Market: By Application, Lifeline Curve
Figure 34 North America Cancer Immunotherapy Market: Snapshot (2023)
Figure 35 North America Cancer Immunotherapy Market: Company Share 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us